A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2019
Price : $35 *
At a glance
- Drugs LY 3009120 (Primary)
- Indications Cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly
- 03 Dec 2018 Status changed from active, no longer recruiting to discontinued.
- 05 Nov 2018 Planned End Date changed from 2 Nov 2018 to 15 Nov 2018.
- 22 Oct 2018 Planned End Date changed from 28 Sep 2018 to 2 Nov 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History